No Data
Beijing Bohui Innovation Biotechnology Group (300318.SZ): Currently, there are no food safety-related testing products available.
On November 29, Beijing Bohui Innovation Biotechnology Group (300318.SZ) stated on the investor interaction platform that the company currently has no food safety related testing products.
Beijing Bohui Innovation Biotechnology Group (300318.SZ): The microfluidic chip used in the company's in vitro diagnostic test reagents is developed and manufactured by the company.
Gelonghui October 31st - Beijing Bohui Innovation Biotechnology Group (300318.SZ) stated on the investor interaction platform that the microfluidic chip used in the company's in vitro diagnostic test reagents is developed and manufactured by the company. Its main purpose is as a liquid reagent carrier, driving the pump valve on the chip through the instrument's gas path module to achieve the directional flow of liquid reagents in the chip, completing the sample extraction, PCR amplification, DNA reverse hybridization, and other detection processes. The microfluidic chip is used in conjunction with the company's detection analyzers to achieve automated testing of molecular diagnostic reagents.
Bohui Innovation: 2024 Third Quarter Report
beijing bohui innovation biotechnology group (300318.SZ) released net income for the first three quarters, with a net income of 23.7177 million yuan, an increase of 67.77%.
beijing bohui innovation biotechnology group (300318.SZ) released the third quarter report of 2024, the company's revenue for the first three quarters was 6...
Beijing Bohui Innovation Biotechnology Group (300318.SZ): The net income in the first three quarters was 23.7177 million yuan, a year-on-year increase of 67.77%.
Gelonghui on October 29th ǀ Beijing Bohui Innovation Biotechnology Group (300318.SZ) released the third quarter report for 2024, with the company achieving a revenue of 0.646 billion yuan in the first three quarters, a 19.85% year-on-year decrease; a net income attributable to shareholders of the listed company of 23.7177 million yuan, a 67.77% year-on-year increase; a net income attributable to shareholders of the listed company excluding non-recurring gains and losses of 15.6564 million yuan, a 29.24% year-on-year increase; and an earnings per share of 0.0290 yuan.
Bohui Innovation Biotechnology Receives 18 Million Yuan to Scrap Rabies Vaccine Clinical Trial
No Data